Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ann Meeker-O’Connell
Observed names:
A Meeker-O’Connell,
Ann Meeker-O'Connell
Institution:
United States Food and Drug Administration
Observed institutions:
United States Food and Drug Administration,
Johnson & Johnson (United States),
Center for Drug Evaluation and Research,
Vertex Pharmaceuticals (United States)
ORCID:
0000-0002-3772-7970
Observed ORCID:
0000-0002-3772-7970
OpenAlex ID:
A5001514040
Enhancing clinical evidence by proactively building quality into clinical trials
2016
·
Ann Meeker-O’Connell
, Coleen Glessner
, et al.
·
Clinical Trials
·
76
PDF
Central site monitoring: Results from a test of accuracy in identifying trials and sites failing Food and Drug Administration inspection
2013
·
Anne S Lindblad
, Zorayr Manukyan
, et al.
·
Clinical Trials
·
53
Regulatory and Scientific Issues Regarding Use of Foreign Data in Support of New Drug Applications in the United States: An FDA Perspective
2013
·
N A Khin
, P Yang
, et al.
·
Clinical Pharmacology & Therapeutics
·
43
Using Registries to Identify Adverse Events in Rheumatic Diseases
2013
·
Geraldina Lionetti
, Yukiko Kimura
, et al.
·
PEDIATRICS
·
39
Improving public health by improving clinical trial guidelines and their application
2017
·
Martin J. Landray
, Jeroen J. Bax
, et al.
·
European Heart Journal
·
28
PDF
Quality by Design in Clinical Trials: A Collaborative Pilot With FDA
2012
·
Kenneth Sprenger
, David Nickerson
, et al.
·
Therapeutic Innovation & Regulatory Science
·
17
Clinical trial quality: From supervision to collaboration and beyond
2018
·
Ann Meeker-O’Connell
, Coleen Glessner
·
Clinical Trials
·
15
PDF
TransCelerate’s Clinical Quality Management System: From a Vision to a Conceptual Framework
2016
·
Ann Meeker-O’Connell
, Leslie M. Sam
, et al.
·
Therapeutic Innovation & Regulatory Science
·
13
PDF
Enhancing Quality and Efficiency in Clinical Development Through a Clinical QMS Conceptual Framework: Concept Paper Vision and Outline
2015
·
Ann Meeker-O’Connell
, Maria Magdalena Borda
, et al.
·
Therapeutic Innovation & Regulatory Science
·
11
PDF
Modernizing Research and Evidence Consensus Definitions: A Food and Drug Administration–National Institutes of Health Collaboration
2025
·
Donna R. Rivera
, Tracy L. Cutler
, et al.
·
JAMA Network Open
·
10
PDF
Optimizing Informed Consent—A Call to Action
2025
·
Nancy E. Kass
, Ann Meeker-O’Connell
, et al.
·
JAMA Health Forum
·
7
The importance of ClinicalTrials.gov in informing trial design, conduct, and results
2025
·
Robert M. Califf
, Tracy L. Cutler
, et al.
·
Journal of Clinical and Translational Science
·
7
PDF
Accelerating evidence generation: Addressing critical challenges and charting a path forward
2024
·
Jeeyon G. Rim
, Jennifer G. Jackman
, et al.
·
Journal of Clinical and Translational Science
·
4
PDF
Can quality management drive evidence generation?
2021
·
Ann Meeker-O’Connell
, Ansalan Stewart
, et al.
·
Clinical Trials
·
4
PDF
Recent Updates to the Declaration of Helsinki: A View from the U.S. Food and Drug Administration
2025
·
Robert M. Califf
, Ann Meeker-O’Connell
, et al.
·
Therapeutic Innovation & Regulatory Science
·
1
Show more works
View as search
Works count:
15
Citation count:
328
H-index:
10
I10-index:
10
Year
Topic
Type